Quick answer
Recurrent glioblastoma has a median survival of only six to eight months and no effective standard therapy. A Phase I trial led by Ji Nan and Zhang Yang at Beijing Tiantan Hospital delivered TX103, an autologous CAR-T therapy targeting B7-H3, directly into the brain by repeated local infusion. In 15 patients, median overall survival was 19.1 months, 12-month survival was 66.7%, and one patient remained tumour-free beyond a year [1][2][4].
Key takeaways
- TX103 targets B7-H3, a protein widely expressed on glioblastoma cells [1].
- It was given by intracranial local infusion, repeated, rather than intravenously [1][3].
- 15 patients with B7-H3-positive recurrent glioblastoma; median OS 19.1 months; 12-month OS 66.7% [2][4].
- No maximum tolerated dose was reached; most adverse events were low-grade cytokine release syndrome, with three serious adverse events [4].
- The recommended Phase II dose was set at 6×10⁷ cells per infusion [4].
Why the delivery route matters
CAR-T therapy has transformed blood cancers but has struggled in solid tumours, and the brain is the hardest case: the blood-brain barrier keeps cells out, the tumour microenvironment suppresses them, and glioblastoma is antigenically heterogeneous. Intravenous CAR-T for brain tumours has generally produced limited persistence and response [1].
Tiantan's answer was to bypass the barrier: infuse the cells into the tumour cavity or cerebrospinal fluid, repeatedly. The trial's immunology supports the approach — CAR-T expansion and cytokine rises were much larger inside the central nervous system than in peripheral blood, and CAR-T signals remained detectable up to 160 days after the last infusion [2].
What the trial found
Among 15 heavily pretreated patients, median overall survival reached 19.1 months and 12-month survival 66.7%. One patient's tumour disappeared and stayed undetectable for more than a year — reported as the longest complete remission for CAR-T in this disease — with later reports describing more than 24 months without recurrence [1][2][5].
Fifteen patients cannot establish efficacy, and there was no randomised control group; historical comparisons of six to eight months are rough. Interferon-γ-related immune activation in cerebrospinal fluid correlated with survival, suggesting a biomarker, but it needs prospective validation. The FDA has granted orphan-drug designation and an international multicentre Phase I is enrolling at Tiantan and Mayo Clinic [2][3].
The condition in context: glioblastoma
Glioblastoma is the most common and most aggressive primary malignant brain tumour in adults.
| Region | What the data shows | Source |
|---|---|---|
| Prognosis | Nearly all tumours recur after surgery, radiotherapy and temozolomide; median survival after recurrence is six to eight months [1]. | Tiantan Hospital [1] |
| Treatment gap | There is no effective standard therapy for recurrence [1]. | Tiantan Hospital [1] |
| China | Tiantan's trial is described as the first clinical trial of B7-H3 CAR-T in recurrent glioblastoma internationally [1]. | Tiantan Hospital [1] |
Because recurrence is near-universal, even a modest survival gain in a Phase I trial attracts attention — while demanding caution about over-interpretation [3].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Survival | Median OS of 19.1 months in recurrent disease, against a historical six to eight [2][4]. | [2][4] |
| Route | Intracranial repeated infusion produced local CAR-T expansion [2]. | [2] |
| Caution | Phase I, 15 patients, no control arm; efficacy unproven [1][3]. | [1][3] |
Availability and limits
- This is an editorial summary of the published Phase I trial and hospital reports, not a treatment offer [1][2].
- TX103 is investigational; it is not approved for clinical use [2].
- The trial enrolled 15 patients at one centre with no control group [1].
- Serious adverse events occurred in three patients; longer safety follow-up is needed [4].
- Eligibility requires B7-H3-positive recurrent tumour and prior standard therapy [1].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my tumour B7-H3-positive and recurrent after standard therapy? | These are the trial's entry conditions [1]. |
| Are trial slots open, and where? | Enrolment is limited and expanding internationally [2]. |
| Which department handles foreign patients, and in what language? | Tiantan is a working hospital we do not book; confirm international-department coordination and language support. |
| What are the risks of intracranial infusion and CRS? | Repeated brain infusions and immune reactions carry real risk [4]. |
Questions patients ask
What is TX103?
An investigational autologous CAR-T therapy targeting B7-H3, given by repeated intracranial infusion, developed by Tiantan Hospital with Tuoxin Tiancheng and Yale's Chen Lieping [1][3].
What were the results?
In 15 patients with recurrent glioblastoma, median overall survival was 19.1 months and 12-month survival 66.7%; one patient had a durable complete remission [2][4].
Where was it published?
Nature Medicine, 6 August 2026 (DOI 10.1038/s41591-026-04557-6) [1][5].
Is it available as treatment?
No — it is investigational; an international multicentre Phase I is enrolling at Tiantan and Mayo Clinic [2].
Is this relevant to international patients?
It is useful context for China's brain-tumour immunotherapy. Tiantan is a working hospital we do not book — contact its international department directly [1].